文献速递耳科与耳神经

高压氧治疗突发性感音神经性聋的系统评价与荟萃分析

Hyperbaric Oxygen Therapy for Patients With Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2022-01-01

结果显示高压氧组平均纯音听阈绝对增益较对照组高10.3 dB(95%CI 6.5-14.1 dB),听力恢复的比值比为4.3(95%CI 1.6-11.7),提示高压氧作为联合治疗的一部分与更好的听力结局相关。

要点

  • 高压氧作为联合治疗的一部分可显著改善突发性感音神经性聋患者的听力结局。
  • 平均纯音听阈绝对增益较对照组高10.3 dB(95%CI 6.5-14.1 dB)。
  • 听力恢复的比值比为4.3(95%CI 1.6-11.7),支持高压氧联合治疗。

核心结论

  • 高压氧作为联合治疗的一部分与突发性感音神经性聋患者听力结局的改善显著相关。

研究设计与样本

  • 系统评价与荟萃分析,检索2000年1月1日至2020年4月30日发表的英文随机对照试验。
  • 最终纳入3项前瞻性随机对照试验,共88例接受高压氧治疗和62例仅接受药物治疗的成人患者。

主要发现

  • 高压氧组与对照组平均纯音听阈绝对增益的组间差异为10.3 dB(95%CI 6.5-14.1 dB;I2=0%),支持高压氧。
  • 听力恢复的比值比为4.3(95%CI 1.6-11.7;I2=0%),支持高压氧。

关键数值与推荐

  • 纳入标准为年龄≥18岁的突发性感音神经性聋患者,且采用美国耳鼻咽喉头颈外科学会的诊断标准。
  • 主要结局为4个低频(0.5、1、2、3或4 kHz)或3个高频(3或4、6、8 kHz)纯音听阈平均的绝对听力增益。
  • 次要结局为听力恢复(纯音听阈平均增益≥10 dB)的比值比和治疗相关不良事件。

临床怎么用

  • 对于突发性感音神经性聋成人患者,可考虑将高压氧作为联合治疗的一部分以改善听力结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sudden sensorineural hearing loss (SSNHL) is an acute, usually unilateral deficit. Systemic and intratympanic steroids are accepted treatments. Although evidence suggests that hyperbaric oxygen therapy (HBOT) may be beneficial, it is not widely offered. OBJECTIVES: To review and evaluate recent evidence of the association of HBOT with hearing outcomes in SSNHL and to determine if HBOT should be a single or part of a combination treatment regimen. DATA SOURCES: Cochrane Central Register of Controlled Trials, PubMed, EMBASE, CINAHL, Web of Science, CAB, ICTRP, Google Scholar, Clinicaltrials.gov, and ISRCTN databases were searched for randomized controlled trials (RCTs) published in English from January 1, 2000, and April 30, 2020. STUDY SELECTION: Prospective RCTs involving only adult participants (≥18 years) with SSNHL and comparing HBOT, as a single or combination therapy, with control therapies, such as steroids and/or placebo. Only RCTs that used the American Academy of Otolaryngology-Head and Neck Surgery's diagnostic criteria for SSNHL were included. DATA EXTRACTION AND SYNTHESIS: Data were extracted independently by 2 researchers. A fixed-effects model was used for analysis and performed from November 30, 2020, to May 20, 2021. MAIN OUTCOMES AND MEASURES: The mean difference in absolute hearing gain recorded by pure-tone audiometric (PTA) thresholds averaged across 4 low (0.5, 1, 2, and 3 or 4 kHz) or 3 high (3 or 4, 6, and 8 kHz) frequencies was the primary outcome. The secondary outcomes were the odds ratio of hearing recovery defined as a hearing gain of ≥10 decibels (dB) in PTA average and treatment-related adverse effects. RESULTS: Of the 826 records initially identified, 358 duplicates and 451 articles were excluded based on article type, title, and abstract. The full texts of 17 articles were reviewed, of which 14 were excluded because they were either not prospective RCTs (11 articles), the participants were less than 18 years old (2 articles), or the PTA was not reported at frequencies of interest (1 article). Three prospective RCTs with a total of 88 participants who received HBOT in the intervention groups and 62 participants who received only medical therapy in the control groups were studied. The intergroup difference in mean absolute hearing gain (mean difference, 10.3 dB; 95% CI, 6.5-14.1 dB; I2 = 0%) and the odds ratio of hearing recovery (4.3; 95% CI, 1.6-11.7; I2 = 0%) favored HBOT over the control therapy. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, HBOT as part of a combination treatment was significantly associated with improved hearing outcomes in patients with SSNHL over control treatments. TRIAL REGISTRATION: PROSPERO Identifier: CRD42020193191.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Joshua TG, Ayub A, Wijesinghe P, et al. Hyperbaric Oxygen Therapy for Patients With Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 34709348. doi:10.1001/jamaoto.2021.2685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。